Aik Goh

Aik Goh serves as the Chief Medical Officer at Reistone Biopharma since May 2018, overseeing the company's asset pipeline, clinical development strategy, clinical trials delivery, and engagement with regulatory authorities. Previously, Aik Goh held leadership roles at GSK from August 2008 to April 2018, including Head of Therapeutic Area for Respiratory Neuroscience, where responsibilities encompassed clinical development and asset life cycle management, and Director of Clinical Development, focusing on assets in the Respiratory and Immuno-inflammation MDC. Earlier experience includes a Clinical Research Fellow position at the University of Aberdeen, conducting research on esophageal adenocarcinoma, and clinical training at NHS Hospitals in surgical oncology. Aik Goh obtained a Doctor of Medicine degree from the University of Aberdeen, alongside MRCS qualifications from The Royal College of Surgeons of Edinburgh and The Royal College of Physicians and Surgeons of Glasgow, and a Bachelor of Medicine, Bachelor of Surgery (MB ChB) from the University of Aberdeen.